BioNTech SE (BNTX) Net Profit Margin: -39.59%
Is BioNTech SE’s net profit margin high or low?
BioNTech SE's net profit margin of -39.59% is 428% below its 5-year average of 12.08%, near the low end of its 5-year range (-39.59%–54.50%).
The net profit margin for BioNTech SE (BNTX) is -39.59% as of Tuesday, June 9, 2026. It is below its 12-month average by 24.16% (-31.89%).
BNTX Net Profit Margin Chart
BNTX Average Net Profit Margin Chart
BNTX Current vs Average Net Profit Margin Chart
BNTX Net Profit Margin Metrics
NET PROFIT MARGIN
-39.59%
NET PROFIT MARGIN AVG TTM
-31.89%
NET PROFIT MARGIN AVG 3Y
3.77%
NET PROFIT MARGIN AVG 5Y
12.08%
NET PROFIT MARGIN AVG 10Y
-26.91%
NET PROFIT MARGIN AVG 15Y
-26.91%
NET PROFIT MARGIN AVG 20Y
-26.91%
CURRENT VS TTM AVG
-24.16%
CURRENT VS 3Y AVG
-1149.44%
CURRENT VS 5Y AVG
-427.73%
CURRENT VS 10Y AVG
-47.10%
CURRENT VS 15Y AVG
-47.10%
CURRENT VS 20Y AVG
-47.10%
BNTX Competitors' Net Profit Margin
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BioNTech SE (BNTX) | — | -39.59% | -31.89% | 3.77% | 12.08% |
| Mettler-Toledo International Inc. (MTD) | $23.50B | 21.59% | 21.94% | 21.74% | 21.20% |
| Waters Corporation (WAT) | $24.19B | 20.30% | 20.93% | 21.85% | 22.39% |
| Moderna, Inc. (MRNA) | $18.94B | -145.16% | -128.24% | -70.25% | -50.87% |
| Hologic, Inc. (HOLX) | $16.97B | 13.80% | 16.70% | 17.87% | 22.37% |
| Veeva Systems Inc. (VEEV) | $27.37B | 28.44% | 27.22% | 24.83% | 24.72% |
| Biogen Inc. (BIIB) | $29.39B | 13.18% | 15.03% | 17.95% | 19.29% |
| DexCom, Inc. (DXCM) | $30.17B | 17.94% | 16.12% | 14.73% | 15.57% |
| Align Technology, Inc. (ALGN) | $12.76B | 10.17% | 10.36% | 10.48% | 22.21% |
| IQVIA Holdings Inc. (IQV) | $31.09B | 8.34% | 8.63% | 8.47% | 7.22% |
Margin Comparison
Operating Margin
-22.6%
Net Profit Margin
-39.6%
BioNTech SE Net Profit Margin Formula & Definition
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
BioNTech SE Net Profit Margin FAQ
- What is the net profit margin for BioNTech SE (BNTX)?
- The net profit margin for BNTX stock is -39.59%.
- Is BioNTech SE's net profit margin high or low?
- BioNTech SE's net profit margin of -39.59% is 428% below its 5-year average of 12.08%, near the low end of its 5-year range (-39.59%–54.50%).
- What is the TTM average net profit margin for BioNTech SE (BNTX)?
- The TTM average net profit margin for BNTX stock is -31.89%.
- What is the 3Y average net profit margin for BioNTech SE (BNTX)?
- The 3Y average net profit margin for BNTX stock is 3.77%.
- What is the 5Y average net profit margin for BioNTech SE (BNTX)?
- The 5Y average net profit margin for BNTX stock is 12.08%.
- What is the 10Y average net profit margin for BioNTech SE (BNTX)?
- The 10Y average net profit margin for BNTX stock is -26.91%.
- What is the 15Y average net profit margin for BioNTech SE (BNTX)?
- The 15Y average net profit margin for BNTX stock is -26.91%.
- What is the 20Y average net profit margin for BioNTech SE (BNTX)?
- The 20Y average net profit margin for BNTX stock is -26.91%.
BioNTech SE Net Profit Margin History
| DATE | NET PROFIT MARGIN |
|---|---|
| 2025-12-31 | -39.59% |
| 2024-12-31 | -24.18% |
| 2023-12-31 | 24.36% |
| 2022-12-31 | 54.50% |
| 2021-12-31 | 54.24% |
| 2020-12-31 | 3.15% |
| 2019-12-31 | -164.92% |
| 2018-12-31 | -37.64% |
| 2017-12-31 | -139.05% |
| 2016-12-31 | 0.00% |
Related Metrics
About BioNTech SE
BioNTech SE, a biotechnology firm, specializes in the creation and marketing of immune-based treatments for malignancies and various infectious diseases. A significant part of its oncology pipeline includes the FixVac cancer vaccine program, which features several candidates in different phases of clinical development: BNT111 is in Phase 2 for advanced melanoma. BNT112 has reached Phase 1/2a for prostate cancer. BNT113 is undergoing Phase 2 investigation for HPV-positive head and neck cancers. BNT114 is in Phase 1 for triple-negative breast cancer. BNT115 is also in Phase 1, targeting ovarian cancer. BNT116 is a preclinical candidate for non-small cell lung cancer. The company also pioneers personalized therapies that target neoantigens, such as Autogene cevumeran (BNT122), which is in Phase 2 for first-line melanoma and Phase 1a/1b for a range of solid tumors. Furthermore, its pipeline includes an mRNA-based intratumoral immunotherapy, SAR441000, currently in Phase 1 for solid tumors, as well as BNT141 and BNT142, also in Phase 1 for multiple solid tumors. BioNTech's portfolio extends to RiboCytokine therapies (BNT151, BNT152, and BNT153) aimed at solid tumors, and cutting-edge chimeric antigen receptor T-cell (CAR T-cell) immunotherapies like BNT211 for various solid tumors and BNT221 for other types of cancer. Immune checkpoint modulators, specifically GEN1046 and GEN1042, are also under Phase 1/2 clinical investigation for solid tumors. Beyond these, the firm is developing BNT321, an IgG1 monoclonal antibody in Phase 2 for pancreatic cancer, and BNT411, a small molecule immunomodulator candidate for solid tumors. Its broader scope encompasses preventative vaccines for illnesses like COVID-19 and Influenza, additional immunotherapies for infectious diseases, and protein replacement therapies designed for rare conditions. To advance its extensive pipeline, BioNTech has forged strategic partnerships with major pharmaceutical and biotechnology firms, including Genentech, Sanofi S.A., Genmab A/S, Pfizer Inc., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., and Regeneron Pharmaceuticals, Inc. Established in 2008, BioNTech SE maintains its principal operations in Mainz, Germany.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Ugur Sahin